What Does Eyevensys Do?

Total employees35
HeadquartersParis
Founded2008

Eyevensys is a private, clinical-stage biotechnology company dedicated to developing and commercializing innovative, non-viral gene therapies for ophthalmic diseases. Its core technology, the Electro-سونoporation System (ESS), allows for the safe and efficient delivery of DNA plasmids encoding therapeutic proteins into the ciliary muscle of the eye. This approach aims to provide sustained therapeutic effects with a single administration, potentially transforming treatments for conditions like Uveitis, Retinitis Pigmentosa, Age-related Macular Degeneration (AMD), and other eye diseases.

Where Is Eyevensys's Headquarters?

HQ Function

The Paris headquarters serves as the company's main operational hub, housing its core research and development laboratories, clinical development teams, and corporate functions.

Notable Features:

Being located within a major hospital campus (Hôpital St Joseph) provides a unique environment that bridges research with clinical application. The facilities are equipped for advanced gene therapy research and ophthalmological studies.

Work Culture:

Eyevensys fosters a highly specialized, research-intensive work culture focused on scientific breakthroughs in gene therapy. The team environment is collaborative, driven by a shared mission to address unmet needs in ophthalmic diseases. Given its biotech nature, it likely involves agile processes and a strong emphasis on data-driven decision-making.

HQ Significance:

The strategic location in Paris, a key European center for biotechnology and pharmaceutical innovation, allows Eyevensys access to top scientific talent, research collaborations, and a supportive ecosystem for life sciences.

Values Reflected in HQ: The headquarters' location within a hospital campus underscores Eyevensys's patient-centric approach and commitment to translating scientific innovation into clinical solutions. The focus on advanced R&D facilities highlights dedication to cutting-edge science.

Location:

While its primary research and corporate functions are centralized at its Paris headquarters, Eyevensys maintains a global outlook. It conducts clinical trials across multiple international sites, including in Europe and North America, and collaborates with a global network of researchers and institutions. Its U.S. subsidiary supports operations and engagement within the significant North American market.

Street Address:

Bâtiment G, Hôpital St Joseph, 185 rue Raymond Losserand

City:

Paris

State/Province:

Île-de-France

Country:

France

Where Else Does Eyevensys Operate Around the World?

Boston, MA/USA

Address: c/o Eyevensys Inc., 125 High Street, Oliver Street Tower, 18th Floor, Boston, MA 02110

Facilitates Eyevensys's therapeutic development and commercialization strategy within the key U.S. ophthalmology market by managing local clinical studies and engaging with American stakeholders and investors.

Buying Intent Signals for Eyevensys

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Eyevensys? Meet the Executive Team

As of April 2025, Eyevensys' leadership includes:

Dr. Raffy Kazandjian - Chief Executive Officer
Prof. Francine Behar-Cohen - Founder & Chief Scientific Officer
Marie-Claude Holna - Chief Operating Officer
Dr. Géraldine Honnet - Chief Medical Officer

Who's Investing in Eyevensys?

Eyevensys has been backed by several prominent investors over the years, including:

Pontifax Venture Capital
Bpifrance (French public investment bank)
Korea Investment Partners (via GHS Fund)
Pureos Bioventures
Boehringer Ingelheim Venture Fund
Karista (formerly CapDecisif Management)
Shinhan Capital (via GHS Fund)
KDB Capital (via GHS Fund)

What Leadership Changes Has Eyevensys Seen Recently?

Hire0
Exits1

Over the last 12 months (from mid-2023 to mid-2024), Eyevensys saw a notable departure in its development leadership. The company continues its clinical advancements under the existing executive team.

Departures

Thierry Bordet, Thierry Bordet departed from his role as Chief Development Officer after contributing to the company's development programs.

What Technology (Tech Stack) Is Used byEyevensys?

Discover the tools Eyevensys uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Eyevensys Email Formats and Examples

Eyevensys likely uses a standard professional email format common in the biotechnology industry. The most probable format combines the first initial and last name of the employee.

[first_initial][lastname]@eyevensys.com

Format

rkazandjian@eyevensys.com

Example

75%

Success rate

What's the Latest News About Eyevensys?

Eyevensys WebsiteFebruary 21, 2024

Eyevensys to Participate in the European Ophthalmology Innovation Summit (EOIS)

Eyevensys announced its participation in the European Ophthalmology Innovation Summit (EOIS) held in Barcelona, Spain, on February 22, 2024. This engagement allows the company to connect with leaders and innovators in the ophthalmology field and showcase its non-viral gene therapy platform....more

Eyevensys WebsiteApril 19, 2023

Eyevensys Presents Positive Preclinical Data for EYS611 in Glaucoma at ARVO 2023 Annual Meeting

Eyevensys announced its presentation of promising preclinical data for EYS611, its gene therapy candidate for lowering intraocular pressure in glaucoma, at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting. The data highlighted the potential of EYS611 as a novel, long-lasting treatment for glaucoma patients....more

PR Newswire / Eyevensys WebsiteJanuary 17, 2023

Eyevensys Appoints Dr. Raffy Kazandjian as Chief Executive Officer

Eyevensys announced the appointment of Dr. Raffy Kazandjian as its new Chief Executive Officer, succeeding Dr. Patricia Zilliox. Dr. Kazandjian brings over 20 years of experience in ophthalmology and biopharmaceutical leadership to steer Eyevensys through its next phase of clinical development and strategic growth....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Eyevensys, are just a search away.